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ABSTRACT
Objective Policy-makers have long argued about the
potential efﬁciency gains and cost savings from
integrating HIV and sexual reproductive health (SRH)
services, particularly in resource-constrained settings with
generalised HIV epidemics. However, until now, little
empirical evidence exists on whether the hypothesised
efﬁciency gains associated with such integration can be
achieved in practice.
Methods We estimated a quadratic cost function using
data obtained from 40 health facilities, over a 2-year-
period, in Kenya and Swaziland. The quadratic
speciﬁcation enables us to determine the existence of
economies of scale and scope.
Findings The empirical results reveal that at the current
output levels, only HIV counselling and testing services
are characterised by service-speciﬁc economies of scale.
However, no overall economies of scale exist as all
outputs are increased. The results also indicate cost
complementarities between cervical cancer screening and
HIV care; post-natal care and HIV care and family
planning and sexually transmitted infection treatment
combinations only.
Conclusions The results from this analysis reveal that
contrary to expectation, efﬁciency gains from the
integration of HIV and SRH services, if any, are likely to
be modest. Efﬁciency gains are likely to be most
achievable in settings that are currently delivering HIV
and SRH services at a low scale with high levels of ﬁxed
costs. The presence of cost complementarities for only
three service combinations implies that careful
consideration of setting-speciﬁc clinical practices and the
extent to which they can be combined should be made
when deciding which services to integrate.
Trial registration number NCT01694862.
INTRODUCTION
Policy-makers and researchers have long argued
about the potential beneﬁts of integrating HIV pre-
vention, treatment and care with sexual and repro-
ductive health (SRH) services in settings with
generalised HIV epidemics. Since the global eco-
nomic crisis, interest in the potential efﬁciency
gains from service integration has increased, as the
ability of developed countries to fulﬁl commitments
to fund the full coverage of HIV programmes in
developing countries has been questioned.1
The notion that efﬁciencies may be gained
through integration of HIV and SRH services has
considerable intuitive and theoretical appeal.
Efﬁciency gains or cost savings may be achieved
through economies of scale and scope. Economies
of scale are deﬁned as cost savings resulting from
an increase in scale of operations. These may occur
when integration results in an increase in demand
and provision of services, hence lowering the unit
cost of production. On the other hand, economies
of scope measure cost savings that occur from pro-
ducing several outputs simultaneously rather than
separately. Economies of scope can arise from (1)
cost complementarity between two outputs or (2)
spreading ﬁxed costs over an expanded output mix.
Cost complementarities occur when adding a new
service reduces the marginal or average incremental
cost of delivering another service. Spreading ﬁxed
costs contributes to economies of scope when
excess capital capacity is reduced by producing
HIV and SRH services together rather than
separately.
Despite the theoretical and policy importance of
this question, very few studies have empirically
evaluated the efﬁciency gains associated with inte-
grated delivery of HIV and SRH services. While
there is a growing body of evidence on the social,
behavioural and health beneﬁts of integrating HIV
services into SRH services,2–4 reviews have consist-
ently noted a substantial dearth of evidence on the
cost savings and improved efﬁciency of delivering
integrated HIV and SRH services.3–7 The few
studies until now suggesting that integration of
HIV services into SRH services yields cost savings
were either conducted at a relatively small scale or
with study designs that were unable to establish
statistically signiﬁcant results.8–12
The objective of this study is therefore to esti-
mate a multi-output cost function for integrated
HIV and SRH service delivery to evaluate the exist-
ence of economies of scale and scope in a sample
of health facilities in Kenya and Swaziland.
METHODS
Theoretical framework
To evaluate the existence of economies of scale and
scope, we estimated a hybrid cost function.13–15
The hybrid cost function combines output
volumes, input prices and organisational variables
to explain total costs of HIV/SRH services. We esti-
mated a quadratic cost function and specify the
cost function as a random effects generalised least
squares (GLS) model with ui∼iid (o, s2u). The quad-
ratic functional form is chosen because unlike the
trans-logarithm functional form, it accommodates
zero values for outputs therefore allowing for
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straightforward identiﬁcation of economies of scope. The func-
tional form is written as
TCit ¼ a0 þ
XM
m
amyðmÞit þ
1
2
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m
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amnyðmÞit y
ðnÞ
it
þ
XP
p
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where TCit represents the total costs for HIV and SRH services.
The superscripts m and p denote the number of outputs and the
number of input factors and subscripts i and t denote the health
facility and the year. yit refers to outputs (in our case m,n=6
HIV/SRH outputs). We include linear terms for input prices
(w), the proportion of clinical staff (c), measures of integration
(i) and quadratic terms for outputs as well as interaction terms
with the outputs. The terms mi and eit represent the ﬁrm-speciﬁc
individual effects and the error term. Finally, α0 is the constant.
Economies of scale and scope
Two distinct concepts of economies of scale apply in a multi-
output (service) setting: service-speciﬁc economies of scale and
ray (overall) economies of scale. Service-speciﬁc economies of
scale (EOS1) occur when increases in service y
1 result in declin-
ing average incremental costs. For example, as the level of a spe-
ciﬁc HIV or SRH services increases, the cost of providing
additional services declines. The degree of service-speciﬁc econ-
omies of scale is given by
EOS1ðymÞ ¼ AIC ðymÞ=CiðyÞ ð2Þ
where AIC (ym) is the average incremental cost of the mth
service. In this case, if EOS1 (y
m) is greater (less) than 1, then
economies (diseconomies) of scale are said to exist for the mth
service.
Ray economies of scale (RES) describe the behaviour of costs
as all outputs are increased by the same proportion. Following
Baumol et al,16 the degree of RES in a multi-output setting is
deﬁned as
RES ¼ CðYÞ=
X
m
ymCmðYÞ ð3Þ
where C(Y) is the total cost of producing all n outputs (Ym)) and
Ci=δC(Y)/δYm is the marginal cost of producing the mth
output.
RES are said to exist if RES >1 and ray diseconomies of scale
are said to exist if RES <1.
The conventional measure of the degree of economies of
scope is deﬁned as the ratio of excess costs of separate produc-
tion to the costs of joint production of all outputs. Therefore,
economies of scope exist when the cost of joint production is
less than the sum of the costs of separately produced outputs or
subset of outputs. However, following Baumol et al,16 when
there are zero values for some output types, as is the case in this
study, weak cost complementarities (WCC) can be used as a suf-
ﬁcient condition for economies of scope. Under this empirical
test, we investigate how an increase in one of the six services
affects the marginal cost of producing the other services. WCC
occurs when increases in one output reduce the marginal cost of
other outputs. This occurs if the expression:
d2C=dYmdYn , 0 andm= n ð4Þ
Equation (4) states that cost complementarities between two
outputs are present when the marginal cost of producing one
output decreases as the quantity of the other output increases.
Data
This paper used data collected as part of a large non-
randomised trial, Integra Initiative (Clinical Trials.gov identiﬁer:
NCT01694862) designed to evaluate the costs and beneﬁts of inte-
grating HIVand SRH services in Kenya, Swaziland and Malawi.17
The Integra Initiative was originally designed as a pre-study/
post-study with pair-matched intervention (integrated) and com-
parison (non-integrated) sites. However, with external donor
activities and evolving national policy the control sites also inte-
grated services during the study period resulting in no distin-
guishable control and intervention sites.
The data used for our empirical analysis contain cost, HIV
and SRH service utilisation information and health facility
characteristics obtained from 40 health facilities observed over a
2-year-period 2008–2009 and 2010–2011 (n=80). The study
sample included 30 health facilities in Kenya and 10 in
Swaziland. Of the 40 health facilities, 80% were public health
facilities, 43% were located in urban areas and 26% were classi-
ﬁed as hospitals with inpatient facilities. The sample included a
range of facility types, including hospitals, health centres, public
health units and SRH clinics.
Written informed consents were obtained for all Integra
Initiative activities.
The variables used in the cost function were constructed as
follows. Total costs (TCit) were calculated as the total economic
costs of service delivery at the health facilities for a given year.
To obtain estimates of total economic costs of HIV/SRH ser-
vices, costs were initially classiﬁed into two main categories:
capital and recurrent costs. Capital costs included buildings,
equipment and training costs. All capital costs were annualised
and discounted at the standard rate of 3%.18 Recurrent costs
included staff salaries, building maintenance (including utility
expenses), drugs, medical and non-medical supplies, transport
and diagnostics. All costs of overhead/administrative and
support departments (laboratory/ pharmacy) were allocated to
the HIV/SRH services using the top-down costing approach.
The top-down costing approach identiﬁes the total resources
required to deliver services and then assigns these resources to
speciﬁc activities or services based on allocation criteria such as
ﬂoor space, personnel hours or activity data.19 Further details of
the costing methods used are reported in detail elsewhere.20
We deﬁne six outputs (yn) measured as the number of visits
for SRH and HIV services. SRH services included family plan-
ning (FP), post-natal care (PNC) and cervical cancer (Ca Cx)
screening. HIV services included counselling and testing for
HIV (HCT), treatment of sexually transmitted infections (STI)
and HIV treatment and care (HIV). Data on the total number of
visits were collected from registers and monthly reports.
Input prices were deﬁned as average annual wages for clinical
and technical staff, and computed as total annual wages for clin-
ical and technical staff divided by the corresponding number of
staff. Information on staff wages was obtained from the
Ministries of Health (MoHs) for the public health facilities and
the non-governmental organisation (NGO) headquarters for the
NGO facilities. Although wages for the public health facilities
did not differ within each employee category, health facilities
exhibited heterogeneous staff mixes and therefore average wages
varied across facilities. Prices of capital stock and equipment
were not included as these were valued using standard national
prices and therefore did not vary across health facilities studied.
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As covariates, we considered the ratio of clinical staff to total
staff as a proxy for the quality of labour complement at each
health facility. We also explored differences in the extent of inte-
gration using a number of measures. First, we used the standard
measure of integration—the range of HIV/SRH services pro-
vided within the facility and the range of HIV/SRH services pro-
vided within the maternal and child health (MCH) unit. To
capture the extent of physical integration, we also included a
variable on the range of HIV/SRH services provided per clinical
room in the MCH unit and the range of HIV/SRH services pro-
vided per clinical staff member per day.
Second, an index of functional integration describing service
utilisation patterns from the client perspective was also used. The
index summarised four characteristics of service delivery: the
extent to which HIV treatment was reported as being offered on
site (or referred for); the range of services reported as received
during the week; the range of services reported as received in a
single consultation and the range of services reported as received
in single visits. The functional integration index was developed
using latent variable techniques with data obtained from ‘client
ﬂow’ surveys. These measures of integration were constructed
using data collected from health facility registers as well as a
client ﬂow analysis and a health facility assessment carried out as
part of the larger Integra Initiative.17 Further details on the cre-
ation of this index are provided in Mayhew et al (S Mayhew, GB
Ploubidis, K Church, et al. Innovation in the evaluation of
service Integration: the Integra Indexes of HIVand Reproductive
Health Integration. Unpublished work, 2014).
We estimate two speciﬁcations of the cost functions using the
measures of integration. The ﬁrst speciﬁcation includes the indi-
vidual measures of integration as covariates, while the second
includes the functional index of integration.
Table 1 provides a descriptive summary of the variables
included in the cost function. All costs and prices are adjusted
to 2014 US$.
RESULTS
The empirical results of the two speciﬁcations of equation (1)
estimated using the quadratic functional form are presented in
table 2. The results of the Hausman speciﬁcation test reveal that
the coefﬁcients estimated by the chosen random effects
estimator are not statistically different from those obtained by
the ﬁxed effects model. This inspires conﬁdence that the model
is correctly speciﬁed.
These results show that only the output coefﬁcients for FP
and HIV outputs are signiﬁcant in both speciﬁcations. While the
coefﬁcients for input prices are both signiﬁcant for the ﬁrst spe-
ciﬁcation, only the price coefﬁcient for clinical staff is signiﬁcant
for the second speciﬁcation. In both speciﬁcations, only the FP
and HIV output coefﬁcients and the clinical staff input price
coefﬁcient have the expected positive sign.
As expected, the effect of range of services per clinical staff
(coefﬁcient I3) was negative and signiﬁcant, which indicates that
an increase in the range of services per clinical staff decreases
costs signiﬁcantly.
Another interesting observation is the positive but not signiﬁ-
cant coefﬁcient for functional integration. This suggests that
functional integration does not have a signiﬁcant effect on costs.
Economies of scale and scope
Table 3 presents the estimated values of economies of scale and
scope. These were estimated using the cost equation (1) and the
formulas speciﬁed in equations (3) and (4) for each of the
health facilities included in the sample. The results suggest that
service-speciﬁc economies of scale exist for only HIV counsel-
ling and testing (HCT) services. However, the estimates of RES
for both speciﬁcations were <1, suggesting that overall econ-
omies of scale do not exist for the HIV and SRH services. These
results further suggest that at their current output levels, the
health facilities included in the sample are not fully exploiting
their potential economies of scale.
We also note signiﬁcantly negative interaction coefﬁcients for
Y1Y5 (FP and STI treatment); Y2Y6 (PNC and HIV care) and
Y3Y6 (Ca Cx screening and HIV care in both speciﬁcations sug-
gesting cost advantages from jointly providing these outputs).
The positive interaction term for Y1Y4 (FP and HCT), although
not signiﬁcant, suggests no cost advantages from jointly produ-
cing these two outputs, which is puzzling.
DISCUSSION
Overall we found that integration, measured using conventional
measures of integration (such as the range of services provided
Table 1 Descriptive statistics of variables used in the empirical study
Variable Variable description Mean SD Min. Max.
Total cost (TC) Total annual HIV and SRH costs (US$ 2014) 258 898.80 501 791.10 2513 2 703 186
y1 Total family planning visits 3887 3592 470 22 094
Y2 Total post-natal care visits 687 867 0 3330
Y3 Total cervical cancer screening visits 203 362 0 2063
Y4 Total HIV counselling and testing visits 2670 2851 0 15 878
Y5 Total STI treatment visits 277 667 0 3702
Y6 Total HIV treatment visits 3747 9917 0 70 605
Pc Average annual wage per clinical staff 9059.68 6480.74 1427.28 37 552.96
Pt Average annual wage per technical staff 3145.69 2675.92 0 11 102.34
I1 Range of HIV/SRH services provided in the facility 6.64 1.09 3 8
I2 Range of HIV/SRH services provided in the MCH unit 2.26 1.14 0 4
I3 Range HIV/SRH service provided per clinical staff per day 1.92 0.97 0 4
I4 Range HIV/STI services provided per room per day 1.26 0.88 0 4
I5 Functional integration index score 0.01 0.94 −1.25 3.59
Cs Proportion of clinical staff 0.49 0.15 0.17 0.95
SRH, sexual reproductive health; STI, sexually transmitted infections.
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in either the facility or the MCH unit), may increase the total
cost of service delivery. However, while a more integrated
service mix as measured by the functional integration has little
impact on total costs, an increase in the range of services pro-
vided by clinical staff can reduce total costs of service delivery.
The disparity in these ﬁndings probably reﬂects the fact that
studies such as these are unable to account for case mix or
quality—and it is conceivable that integration may improve
both, but at additional cost. The increased total cost from the
range of services may, for example, reﬂect a more comprehen-
sive, higher quality service offered for FP clients.
The ﬁndings on the impact of integration on cost are further
reﬁned through our examination of economies of scale and
scope—which provides additional insight into which combina-
tions of SRH/HIV services are likely to achieve the most cost
savings. We found evidence of service-speciﬁc economies of
scale for STI and HCT services, in line with other studies,21–23
but no evidence of global economies of scale in integrated SRH/
HIV services—as all services are expanded. This may reﬂect the
extent to which these particular services rely on ‘ﬁxed’ staff and
capital costs, rather the relatively high variable costs common in
HIV care and treatment.
The positive signiﬁcant coefﬁcients on the scope effect for FP
and HCT services suggest that these services could be provided
independently without signiﬁcant negative effects on costs.
While it has been argued that there is a low marginal cost to
providing HCT during a FP visit,24 FP and HCT services in
practice may have different patterns of resource requirements.
Counselling for HIV may be provided together with FP counsel-
ling with no additional resource requirement; however, testing
for HIV requires not only additional staff time but also equip-
ment and supplies to process the test results, and therefore in
practice there may be limited savings from these speciﬁc services
being jointly provided.
Some limitations of this study should be noted. First,
although this is one of the largest studies until now on the
impacts of integrating HIV and SRH services in a low-income
and middle-income setting, the results obtained from this study
lack the statistical power of larger panel data sets. This limits the
strength of the conclusions that can be drawn. Also, although
the study captures the heterogeneity in health facilities in terms
of HIV and SRH services provided, no case mix variables were
able to be included to control for complexity of services pro-
vided because of unavailability of such data in the study setting.
Finally, as with all studies of this kind, we cannot establish caus-
ality, due to the lack of an experimental design. However, the
approach we adopt is commonly accepted as a sound basis for
exploring associations. There are substantial challenges in con-
trolling for the level of integration in real-world settings,
meaning that few have succeeded until now to provide experi-
mental evidence in this respect.
Despite these limitations, our ﬁndings have implications for
both the planning for and the organisation of HIV and SRH ser-
vices at the facility level generally. First, while the intuitive case
for integration remains strong, in practice only some forms of
integration may have this consequence. The results of this study
have shown that efﬁciency gains from joint production are
dependent on the speciﬁc combination of resources used for dif-
ferent services. These may vary by setting but, in general, this
study adds to the evidence that HIV and SRH services that have
substantial ﬁxed costs are most likely to exhibit economies of
scale. The speciﬁc costs that are ﬁxed will, however, vary by
setting. For example, in rural settings, stafﬁng complements may
be ﬁxed; and therefore there may be substantial gains by
Table 3 Estimates of economies of scale and weak cost
complementarities (WCC)
Service-specific economies of scale
Y1 (FP) 0.005
Y2 (PNC) 0.001
Y3 (Ca Cx screening) 0.002
Y4 (HCT) 1.002
Y5 (STI treatment) 0.039
Y6 (HIV care) 0.158
Ray economies of scale −0.001
WCC
Y1 (FP)×Y4 (HCT) 0.03
Y2 (PNC)×Y4 (HCT) 0.03**
Y3 (Ca Cx screening)×Y4 (HCT) 0.02
Y1 (FP)×Y5 (STI treatment) −0.10***
Y2 (PNC)×Y5 (STI treatment) −0.06*
Y3 (Ca Cx screening)×Y5 (STI treatment) −0.57***
Y1 (FP)×Y6 (HIV care) −0.00
Y2 (PNC)×Y6 (HIV care) −0.03**
Y3 (Ca Cx screening)×Y6 (HIV care) −0.13***
***, ** and * denote significance at the 1%, 5% and 10% levels, respectively.
FP, family planning; PNC, post-natal care; STI, sexually transmitted infections.
Table 2 Regression results of the GLS model
Dependent
variable= (total
annual cost)
Specification 1 Specification 2
Coeff. SE Coeff. SE
Y1 48.02** 19.972 40.883* 21.803
Y1Y1 −0.0061 0.0001 0.00020 0.0011
Y2 13.20 89.551 −12.99976 95.088
Y2Y2 −0.0279 0.0339 −0.019 0.036
Y3 539.77*** 201.760 −188.9234 197.664
Y3Y3 0.2227** 0.0974 0.116 0.103
Y4 −49.747** 22.231 −10.55806 23.459
Y4Y4 0.0012 0.0016 0.001 0.001
Y5 −460.208*** 138.453 −212.193 144.959
Y5Y5 0.502*** 0.071 0.429*** 0.073
Y6 25.617** 10.241 35.556*** 9.224
Y6Y6 0.0026*** 0.0006 0.002*** 0.0007
Y1Y4 0.0256 0.005 −0.001 0.005
Y1Y5 −0.1000*** 0.020 −0.103*** 0.020
Y1Y6 −0.0017 0.0015 −0.003** 0.001
Y2Y4 0.031** 0.073 0.017 0.015
Y2Y5 −0.062* 0.035 −0.010 0.038
Y2Y6 −0.033*** 0.008 −0.026** 0.009
Y3Y4 0.023 0.0211 0.001 0.023
Y3Y5 −0.575*** 0.170 0.280 0.184
Y3Y6 −0.132*** 0.034 −0.096*** 0.037
Pc 16.22*** 5.003 24.882*** 5.359
Pt −20.47** 8.575 −13.322 9.457
I1 20 610.82 26 131.61 – –
I2 159 054.8*** 40 892.33 – –
I3 −180 977.2*** 40 672.14 – –
I4 26 846.94 32 925.64 – –
I5 – – 773.3802 20 381.52
Cs −60 292 141 372.9 −117 282.9 159 463.1
Intercept −94 982.13 121 136.5 −41 241.97 100 017.1
N 80 80
***p<0.01, **p<0.05, *p<0.10.
Y1, family planning visits; Y2, post-natal care visits; Y3, Ca Cx visits; Y4, HCT visits;
Y5, sexually transmitted infection visits; Y5, HIV visits.
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increasing the volume of services provided by this minimum staff-
ing complement, through increasing the range of services
offered. With respect to economies of scope, this study suggests
that planners in all settings need to carefully consider the detailed
processes and clinical practice required by each service, and
which of these can be combined when services are integrated,
before assuming substantial cost advantages. The extent to which
the speciﬁc ﬁndings of this study can be directly generalised
depends on how similar the process of service delivery and clin-
ical practice are to those observed here. Finally, it should be
noted that integration has many aims (and consequences) and
that the considerations above are only one factor in the optimal
service design. As such, careful consideration should be made to
optimally balance cost with other service delivery aims.
CONCLUSION
This paper sets out to evaluate the existence of economies of
scale and scope. We estimated a quadratic cost function using
data obtained from 40 health facilities providing integrated HIV
and SRH services in Kenya and Swaziland. The results from this
analysis reveal that contrary to expectation, efﬁciency gains that
can be reasonably expected from integration of HIV and SRH
services, if any, are likely to be low.
Key messages
▸ Efﬁciency gains that can be reasonably expected from
integration of HIV and sexual reproductive health services, if
any, are likely to be modest.
▸ No evidence of overall economies of scale suggesting that
health facilities included in the sample are not exploiting
potential economies of scale.
▸ Cost complementarities were found for cervical cancer
screening and HIV treatment; family planning and sexually
transmitted infection treatment and post-natal care and HIV
treatment only.
▸ The extent to which the speciﬁc ﬁndings of this study can be
directly generalised depends on how similar the process of
service delivery and clinical practice are to those observed here.
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